Get the Stockscreener App
1.28
2.29%
-0.03
After Hours:
1.31
0.03
+2.34%
Oncolytics Biotech Inc stock is traded at $1.28, with a volume of 920.71K.
It is down -2.29% in the last 24 hours and up +48.79% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.31
Open:
$1.31
24h Volume:
920.71K
Relative Volume:
0.74
Market Cap:
$128.46M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-4.8393
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
+20.75%
1M Performance:
+48.79%
6M Performance:
+103.17%
1Y Performance:
+33.51%
1-Day Range:
$1.25
$1.33
1-Week Range:
$1.14
$1.44
52-Week Range:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.28 | 132.63M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech (TSE:ONC) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Will Oncolytics Biotech's (ONCY) Upcoming CEO Presentation Reinforce Management Credibility Among Investors? - simplywall.st
FDA Accelerates Cancer Drug Pipeline as Market Momentum Surges Past $400B - Baystreet.ca
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market - The Malaysian Reserve
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions - Cantech Letter
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Premarket Movers: RAPP, MCRB, JAGX. MEIP… - RTTNews
Oncolytics Biotech Reports Promising Results in Metastatic Colorectal Cancer Studies - TipRanks
Is Oncolytics Biotech Inc. a speculative investmentNew Guidance & High Accuracy Swing Entry Alerts - خودرو بانک
What’s next for Oncolytics Biotech Inc. stockEarnings Recap Report & Stepwise Swing Trade Plans - خودرو بانک
What is Oncolytics Biotech Inc.’s TAM (Total Addressable Market)Weekly Investment Summary & Weekly High Return Forecasts - خودرو بانک
Multi asset correlation models including Oncolytics Biotech Inc.2025 Top Gainers & High Accuracy Buy Signal Tips - Newser
Will Oncolytics Biotech Inc. stock recover after recent dropBond Market & Fast Entry and Exit Trade Plans - Newser
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
Technical signs of recovery in Oncolytics Biotech Inc.2025 Macro Impact & Reliable Volume Spike Trade Alerts - Newser
Chart overlay techniques for tracking Oncolytics Biotech Inc.Trade Analysis Report & Low Drawdown Investment Strategies - Newser
Does Oncolytics Biotech Inc. meet Warren Buffett’s criteriaWeekly Market Summary & Daily Entry Point Trade Alerts - خودرو بانک
How to manage a losing position in Oncolytics Biotech Inc.Quarterly Portfolio Report & Real-Time Volume Analysis - Newser
Does Oncolytics Biotech Inc. show high probability of reboundEarnings Growth Report & Entry Point Strategy Guides - Newser
Leading vs lagging indicators on Oncolytics Biotech Inc. performance2025 Trade Ideas & AI Based Buy/Sell Signal Reports - Newser
How to forecast Oncolytics Biotech Inc. trends using time seriesQuarterly Earnings Report & Consistent Profit Trading Strategies - Newser
Can Oncolytics Biotech Inc. navigate macro headwindsWeekly Loss Report & Daily Risk Controlled Trade Plans - خودرو بانک
Can swing trading help recover from Oncolytics Biotech Inc. lossesMarket Volume Report & Safe Entry Point Alerts - Newser
Can Oncolytics Biotech Inc. reach all time highs this yearGlobal Markets & Momentum Based Trading Ideas - خودرو بانک
Is Oncolytics Biotech Inc. likely to announce a buybackAnalyst Downgrade & Safe Capital Growth Trade Ideas - خودرو بانک
Is Oncolytics Biotech Inc. still worth holding after the dip2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
Oncolytics Biotech Inc. stock retracement – recovery analysisTrade Ideas & Verified Technical Signals - Newser
Applying big data sentiment scoring on Oncolytics Biotech Inc.Market Sentiment Summary & High Conviction Buy Zone Picks - Newser
Quantitative breakdown of Oncolytics Biotech Inc. recent moveWeekly Profit Report & Fast Gaining Stock Reports - Newser
Can momentum traders help lift Oncolytics Biotech Inc.July 2025 Outlook & Fast Entry High Yield Tips - Newser
Can Oncolytics Biotech Inc. stock outperform in a bear marketPortfolio Growth Summary & High Win Rate Trade Tips - خودرو بانک
How to use a screener to detect Oncolytics Biotech Inc. breakoutsMarket Growth Summary & Fast Gain Swing Trade Alerts - Newser
Cellectar Biosciences shares fall 1.24% premarket as Oncolytics Biotech Inc. gains FDA approval for breakthrough therapies. - AInvest
How hedge fund analytics apply to Oncolytics Biotech Inc. stock2025 Valuation Update & Advanced Technical Analysis Signals - Newser
What’s the recovery path for long term holders of Oncolytics Biotech Inc.Earnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
Oncolytics Biotech shares rise 8.70% premarket after providing updated clinical safety data for pelareorep. - AInvest
What technical models suggest about Oncolytics Biotech Inc.’s comebackWeekly Stock Report & Safe Capital Growth Trade Ideas - Newser
What moving averages say about Oncolytics Biotech Inc.Inflation Watch & Target Return Focused Picks - Newser
Using data filters to optimize entry into Oncolytics Biotech Inc.July 2025 Short Interest & Verified High Yield Trade Plans - Newser
Tools to assess Oncolytics Biotech Inc.’s risk profileGap Down & Fast Entry and Exit Trade Plans - Newser
Does Oncolytics Biotech Inc. qualify in momentum factor screening2025 Market Sentiment & Safe Entry Trade Reports - Newser
Using portfolio simulators with Oncolytics Biotech Inc. included2025 Top Decliners & Long-Term Safe Investment Plans - Newser
FDA Fast-Track Cancer Treatments Drive Market Surge as Innovations Accelerate - Baystreet.ca
Oncolytics Biotech Inc. recovery potential after sell off2025 Top Decliners & Fast Gain Swing Trade Alerts - Newser
Trend analysis for Oncolytics Biotech Inc. this weekJuly 2025 Institutional & Technical Buy Zone Confirmation - Newser
Cellectar Biosciences shares fall 1.45% after-hours as Oncolytics Biotech Inc. gains regulatory momentum. - AInvest
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):